Çѱ¹º¸°ÇÀÇ·á±â¼úÆò°¡ÇÐȸ(ȸÀå ¾çºÀ¹Î)°¡ ¿À´Â 5ÀÏ ¼÷¸í¿©ÀÚ´ëÇб³ ¹éÁֳ⠱â³ä°ü 2Ãþ »ï¼º ÄÁº¥¼Ç ¼¾ÅÍ¿¡¼ Ãß°è Çмú´ëȸ ¹× ±¹Á¦ ½ÉÆ÷Áö¾öÀ» °³ÃÖÇÑ´Ù.
ÀÌ Çà»ç´Â ÃÖ±Ù º¸°ÇÀÇ·á ºÐ¾ß¿¡¼ Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ´Â °æÁ¦¼ºÆò°¡¸¦ ´Ù°¢ÀûÀ¸·Î ³íÀÇÇÏ°í °ü·Ã ½Ç¹«ÀÚ¿¡°Ô ±³À° ±âȸ¸¦ Á¦°øÇÔÀ¸·Î½á »ê,ÇÐ,°üÀÇ °øµ¿¹ßÀü¿¡ ±â¿©Çϱâ À§ÇØ ¸¶·ÃµÆ´Ù.
À̹ø Çмú´ëȸ°ú ±¹Á¦ ½ÉÆ÷Áö¾öÀº ¡â1ºÎ Çмú´ëȸ (ÀÚÀ¯ ¿¬Á¦ ¹ßÇ¥: ¿ÀÀü 9½Ã ~ 11½Ã 20ºÐ) ¡â2ºÎ ÃÑȸ (¿ÀÀü 11½Ã 20ºÐ ~ 12½Ã) ¡â3ºÎ ±¹Á¦ ½ÉÆ÷Áö¾ö (¿ÀÈÄ 1½Ã 30ºÐ ~ 6½Ã)ÀÇ ÀÏÁ¤À¸·Î ÁøÇàµÈ´Ù.
1ºÎ Çмú´ëȸ¿¡¼± ÀÚÀ¯ ¿¬Á¦ ¹ßÇ¥°¡ ÆîÃÄÁø´Ù.
±¹Á¦ ½ÉÆ÷Áö¾öÀº ¼¿ï´ëÇб³ º¸°Ç´ëÇпø ¾çºÀ¹Î ±³¼ö°¡ ÁÂÀåÀ» ¸Ã°í, ¼¼ ¸íÀÇ ¿¬ÀÚ°¡ ¡®HTA in Pharmaceutical Policy Decision Making'¶ó´Â ÁÖÁ¦·Î ¹ßÇ¥¿¡ ³ª¼±´Ù.
Michael Drummond (Professor of Health Economics, University of York, UK)´Â NASTY OR NICE? A perspective on Health Technology Assessment in the United Kingdom¶ó´Â ¼¼ºÎ ÁÖÁ¦·Î, Andrew Mitchell (Strategic Adviser, Evaluation, Australian Government Department of Health and Ageing, Australia)´Â HTA in Pharmaceutical Policy Decision Making: an Australian Perspective, Michael Reich(Professor, Harvard School of Public Health, USA)´Â Challenges of Implementation: Implications for Korea's Policy on Economic Evaluation of Medicines¶ó´Â ¼¼ºÎ ÁÖÁ¦¸¦ ¹ßÇ¥ÇÏ°í ÁúÀÇÀÀ´ä ½Ã°£À» °¡Áö°Ô µÈ´Ù.
Åä·Ð¿¡¼´Â ¾÷°è, Çаè, °ø°ø(°ø´Ü, ½ÉÆò¿ø)¿¡¼ÀÇ Àü¹®°¡µéÀÌ Âü¼®ÇÏ¿© º¸°ÇÀÇ·á±â¼úÆò°¡¸¦ À§ÇØ ´Ù°¢ÀûÀÎ ³íÀÇÀÇ ÀåÀ» ¸¶·ÃÇÑ´Ù.
ÇÐȸ´Â ÀÌ¿Í ÇÔ²² PC¸¦ ÀÌ¿ëÇÑ ÀǾàÇ° °æÁ¦¼º Æò°¡ ½Ç½À¿¡ ´ëÇÑ ¿¬¼ö±³À°µµ ½Ç½ÃÇÑ´Ù.
6ÀÏ ¼÷¸í¿©ÀÚ´ëÇб³ ¹éÁֳ⠱â³ä°ü 402È£¿¡¼ ¿¸®´Â ¿¬¼ö±³À°¿¡¼´Â ¡â°áÁ¤ºÐ¼®¡â¸¶¸£ÄÚÇÁ ¸ðµ¨ µîÀ» ´Ù·é´Ù.
±âŸ ÀÚ¼¼ÇÑ ¹®ÀÇ´Â ¼÷¸í¿©ÀÚ´ëÇб³ ÀÓ»ó¾àÇдëÇпø ³» Çѱ¹º¸°ÇÀÇ·á±â¼úÆò°¡ÇÐȸ(ÀüÈ: 02-6395-1214, À̸ÞÀÏ: khta06@naver.com)·Î ÇÏ¸é µÈ´Ù.